Axsome Therapeutics, Inc. (AXSM)
After hours:
| Previous close | 93.69 |
| Open | 94.17 |
| Bid | 92.97 x 100 |
| Ask | 118.66 x 200 |
| Day's range | 91.52 - 94.53 |
| 52-week range | 55.02 - 98.40 |
| Volume | |
| Avg. volume | 651,022 |
| Market cap | 4.473B |
| Beta (5Y monthly) | 1.25 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.58 |
| Earnings date | 04 Nov 2024 - 08 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 125.88 |
ZacksFDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up
The FDA accepts Axsome's resubmission of the NDA for AXS-07 for the acute treatment of migraine. A decision is due on Jan. 31, 2025. Shares rise.
GlobeNewswireAxsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
FDA sets PDUFA action goal date of January 31, 2025NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the Company’s New Drug Application (NDA) for AXS-07 for the acute treatment of migraine. The FDA designated the resubmission as
- GlobeNewswire
Axsome Therapeutics to Participate in Investor Conferences in September
Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 in New York Wells Fargo Healthcare Conference on September 5 in Boston Baird 2024 Global Healthcare Conference on September 11 in New York Cantor Global Healthcare Conference on September 18 in New York NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, will par
